BI-1230 is a potent inhibitor of HCVNS3 protease, exhibiting efficacy in the low nanomolar range, and notably suppresses viral replication. This compound demonstrates high selectivity, distinguishing effectively between other serine cysteine proteases. Additionally, BI-1230 exhibits favorable pharmacokinetic (PK) properties[1].
Ciluprevir is an effective and selective HCVNS3 protease inhibitor with proven antiviral effect in humans. Ciluprevir may be an antiviral agent for individuals infected with non-genotype-1 HCV. In vitro sensitivity studies with Ciluprevir showed a decrea
Vedroprevir, also known as GS9451, is a selective hepatitis C virus (HCV) NS3 protease inhibitor in the development of the treatment of genotype 1 (GT1) HCV infection.
Hepatitis Virus C NS3 Protease Inhibitor 2 is a peptide inhibitor derived from a product that targets the NS3 protease of the hepatitis C virus (HCV). Its inhibitory activity against the NS3 protease is characterized by a Ki value of 41 nM.
BI-1388 is a highly potent inhibitor of HCVNS3 protease activity, inhibiting viral replication for various HCV genotypes and for resistant mutants D168V and R155K.
Faldaprevir sodium is a potent NS3 NS4A protease inhibitor potentially for the treatment of HCV infection. Faldaprevir is known to inhibit P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1.